The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation
NCT00674453
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
51
Enrollment
INDUSTRY
Sponsor class
Conditions
Bone Loss
Interventions
DRUG:
Lasofoxifene
OTHER:
Placebo
Sponsor
Ligand Pharmaceuticals